Elevated levels of TAp63 are associated with adverse clinical course and chemoresistance in CLL. (A) TAp63 mRNA expression levels in different subgroups of CLL patients. TAp63 mRNA expression is significantly higher in U-CLL (n = 89) compared with M-CLL (n = 77), and the same pattern is observed between TAp63^high (n = 49) and TAp63^low (n = 117) cases. (B-C) Kaplan Meier curves for time to first treatment (TTFT) and overall survival (OS). TAp63^high CLL patients exhibit shorter TTFT (B) (P = .03) (TAp63^highmedian TTFT, 1.58 years; TAp63^lowmedian TTFT, 4.07) and shorter OS (C) (P = .04) (TAp63^highmedian OS, 7.825 years; TAp63^lowmedian OS, undefined due to the large number of censored cases) compared with TAp63^low cases. (D) TAp63 mRNA expression levels over the disease course. CLL patients at disease express higher TAp63 mRNA levels compared with the timepoint of diagnosis (FD, 3.47; P = .02). *P ≤ .05, ****P ≤ .0001.